Oncolytic viruses are a novel class of anticancer agents that attract increasing clinical attention. Currently, more than 20 viruses have been shown to possess oncotropic and oncolytic features. In the last years, compelling evidence accumulated that the small autonomous parvoviruses can achieve complete cure of various tumors in animal models, and kill tumor cells that resist conventional anticancer treatments. wt H-1PV is currently subjected to a phase I/IIa clinical trial, in which the virus is administered to patients with recurrent glioblastomamultiforme. As recently demonstrated the adjuvant capacity of oncolytic H-1PV can be increased by incorporating immunostimulatory CpG motifs into the viral single-stranded DNA genome in order to enhance innate immune TLR-9 signalling. Virus-mediated delivery of the immune-priming CpG elements to tumor cells leads to their further amplification together with the viral genome. Antitumor activity was evaluated in a protocol where cells were infected with wt H-1PV or CpG-modified viruses, lethally irradiated and administered subcutaneously to serve as an autologous therapeutic vaccine for the treatment of hepatoma lung metastases.
What are the Implications of Distinct HPV Genotypes in Women of Different Ethnic/Racial Ancestry?: Adriana C. Vidal, Susan K. Murphy and Cathrine Hoyo
Last date updated on July, 2014